The importance of closing the women’s health gap

3+ minutes

The healthcare system has historically left women in poorer health compared to their male counterparts. We refer to this as the women’s health gap. Its essence: if you are a woman or were born with female biology, you are more likely to be misunderstood, dismissed, neglected, misdiagnosed or down right ignored by your healthcare practitioners.  

We’ve known about this mistreatment for some time. Many women learn early on in life that living in pain is ‘normal’ for them and are told to ‘just get on with it’. They are expected to go through painful procedures, such as IUD insertions, without any pain medication. With men, on the other hand, pain is treated with much more caution and concern. It isn’t dismissed as ‘part of manhood’.  

There is also a historical and on-going underrepresentation of women in clinical trials, meaning that most medicines, diagnostics, and devices work better on people with male biology. Quite incredulously, women are 50% more likely to get misdiagnosed after a heart attack, reducing their chances of getting the correct, life-saving treatment. 

And the conditions that don’t affect men specifically lack proper funding and any real understanding, even in 2026. Endometriosis, a chronic and debilitating gynecological disease affecting 10% of the female population, continues to remain a medical mystery with no cure in sight.   

Closing the women’s health gap means getting answers. It means being heard, seen, and not expected to live in pain. And most critically, it means providing women with more accurate diagnoses and better treatments; to save lives and improve quality of living for half the global population.  

 

The funding gap 

Women-specific conditions, such as maternal, menopausal, fertility and hormonal health, receive just 4% of biopharma R&D spending. Out of all the money that biotechnology and pharmaceutical companies spend to discover, test, and develop new medicines – a mere 4% feels incredibly unjust.   

Here’s another startling fact: A McKinsey report published in 2024 found that, between the years 2019 and 2023, 11 erectile dysfunction (ED) startups attracted 28 times more capital than 8 endometriosis-related ventures. While both conditions affect about 10% of their respective populations, ED, at its worst, can prevent a couple from conceiving. Endometriosis, on the other hand, not only causes infertility, but also debilitates women, leaving them struggling with crippling, fully body complications for much of their lives.  

According to the Women’s Resource Centre: “While we’re seeing increasing recognition that systems have failed women, and that those failures are structural, not incidental [...] we’re still relying on funding models that reproduce those same patterns of instability and underinvestment.” 

Funding shapes outcomes. So how can the women’s health sector gain momentum if the area continues to lack long-term financial security?  

 

Where are we making progress?   

As mentioned above, we are absolutely seeing more recognition of how our healthcare systems have been failing women. In recent years, there has been more awareness, more involvement, and more outrage at how women have continually been mistreated by a system that is designed to help them.  

Essentially, women have woken up to the discriminatory attitudes and behaviors of their doctors and healthcare practitioners. Injustices are more visible – how is it fair that women are expected to undergo coil insertions without pain relief, while men receive local anesthetic to have a catheter inserted? 

There is also less stigma attached to certain women-specific conditions. Periods are less taboo. It’s fairly common to see free menstrual products in public toilets. Menopause symptoms are more well-known, and some workplaces are introducing menopausal benefits. Generally, more open conversations are being had about hormonal, gynecological and maternal conditions.  

In terms of healthcare areas, we’ve seen advancements in fem tech – with period tracking and fertility apps and devices like the aura ring becoming much more widespread. Huge strides have been made in breast cancer treatments too.  

But most other conditions predominantly affecting women continue to lack ample research, funding and innovation.  

 

The importance of closing this gap 

To put it simply: women deserve better. Better diagnoses, better treatment plans, better understanding and validation of their pain.  

Hundreds of thousands of women live with uncertainty around their hormonal health. Might they have PMOS, endometriosis, or some kind of deficiency? Do they have a condition that might make it harder for them to conceive?  

It’s time that healthcare professionals are able to provide answers to the questions that have long been dismissed. There’s plenty of capital available; it just needs to be spread more evenly, with a fairer portion being channeled towards women’s health and women-specific conditions.  

Meet Life Sciences. Meet Life Sciences Ltd (No.06972871) a company registered in England and Wales at Irongate House, 22-30 Dukes Place, London, EC3A 7LP.
venn
Website by Venn